Olivier Hermine
Professor of Hematology
Hopital Necker / Universite Paris Cite · Paris, France
Renowned French hematologist and member of the French Academy of Sciences. Key contributor to European MCL Network trials and MCL biology research.
Erratum: Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 14, 2026
Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.
Bone marrow transplantation · Jul 9, 2026
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 1, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial.
HemaSphere · May 1, 2026
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.
Blood advances · Jan 13, 2026
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.
Haematologica · Oct 30, 2025
How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.
Bone marrow transplantation · Jun 1, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.
Blood cancer journal · Apr 24, 2025
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.
British journal of haematology · Jan 1, 2025
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.
Leukemia · Dec 1, 2024
Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.
Haematologica · Nov 1, 2024
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.
Blood · Jul 18, 2024
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Mar 1, 2024